Innovent Biologics posted a net loss of 1.72 billion yuan for 2019. Photo: Handout

Chinese cancer drugs developer Innovent joins a crowded field in search of coronavirus cure

  • Innovent Biologics is working on an antibody drug even as others are developing vaccines because the coronavirus mutates rapidly, says chairman Michael Yu Dechao
  • Innovent posts annual loss of 1.72 billion yuan (US$242.2 million), while sales of its cancer therapy drug sintilimab jumps to over 1 billion yuan
Topic |   Coronavirus China
Innovent Biologics posted a net loss of 1.72 billion yuan for 2019. Photo: Handout
READ FULL ARTICLE